CA-ARCULES
11.2.2020 17:32:06 CET | Business Wire | Press release
Arcules , leading innovators in integrated video and access control cloud services, today announced the commercial availability of the Arcules-XProtect Hybrid™ VMS Solution in North America and Europe. The solution represents a combination of the Arcules Video Surveillance as a Service (VSaaS) integrated with Milestone XProtect Corporate on-premise video management software (VMS). The result is a flexible and feature-rich hybrid video surveillance solution ideal for organizations looking to centralize their dispersed video surveillance operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005274/en/
With Arcules-XProtect Hybrid VMS Solution, Milestone XProtect customers can deploy remote sites quickly, with minimal IT resources and downtime while still benefiting from the strong capabilities of XProtect on-premise VMS. Additionally, Arcules’ intuitive platform provides sites and cameras connected to Arcules VSaaS an underlying cloud infrastructure such as compatibility between sites, low video latency, data encryption, redundancy, streamlined maintenance with automatic updates, and easy onboarding.
“Milestone resellers and end customers are planning their deployment to take advantage of the many benefits of cloud computing. This integration gives Milestone XProtect Corporate customers a new hybrid cloud computing deployment option,” said Bjørn Skou Eilertsen, CTO of Milestone Systems. “The typical Milestone XProtect Corporate user has many branch offices of different sizes and locations. Enabling this hybrid deployment option can allow them to simplify large scale deployments. After the Arcules system is Interconnected the user can utilize these Arcules connected cameras with the advanced XProtect Corporate product capabilities.”
The Arcules-XProtect Hybrid VMS Solution uses Milestone Interconnect™ technology to combine the hyper-scalability and licensing flexibility of Arcules cloud service with the feature-rich video management functions of XProtect Corporate. The combination of these advanced technologies provides uniform access to live video, recordings and alarms across cameras physically connected on-premise and virtually connected via the Arcules cloud, through XProtect Smart Client, XProtect Smart Wall, and the web and mobile clients.
Organizations with distributed locations such as healthcare, retail, corporate campuses and education, and utility environments all benefit from high-performance cloud services to provide real-time insight in the event of an incident in remote areas. The Arcules-XProtect Hybrid VMS Solution also adds value to monitoring stations and law enforcement organizations that use XProtect Corporate as their VMS platform. Such organizations can now access cameras and customers subscribed to the Arcules cloud service directly from their on-premise XProtect system.
“The Arcules-XProtect Hybrid VMS Solution is an ideal solution for businesses looking to expand their surveillance operation across geographically dispersed locations,” said Arcules CEO Andreas Pettersson. “These businesses can enjoy the strong capabilities of on-premise VMS while reducing their capital investment. The solution also enables organizations to better manage their operational costs as a result of flexible pricing schemes and minimal hardware requirements.”
The Arcules-XProtect Hybrid VMS Solution regional availability outside of North America and Europe is based on market demand conditioned by datacenter availability and/or the possibility to utilize data centers in other regions.
Arcules will demonstrate the solution in booth #809 at the MIPS 2020 Conference , February 17-19, at the Gaylord Texan in Grapevine, TX as well as in Arcules booth #31081 and Milestone booth #18053 during the 2020 ISC West Conference and Expo , March 17-20, at the Sands Expo in Las Vegas.
About Arcules
Arcules, a Canon Group company, addresses the unmet need of modern enterprises for integrated cloud-based video surveillance, access control and analytics. Using the latest developments in cloud, artificial intelligence and machine learning, Arcules combines previously untapped video monitoring data with sensor data and analytics to deliver actionable insights that ultimately drive better business decisions, optimize operations and improve safety. Arcules is headquartered in Irvine, Calif. Visit www.arcules.com for more information and follow us on LinkedIn , Facebook , and Twitter .
About Milestone Systems
Milestone Systems is a leading provider of open platform video management software; technology that helps the world see how to ensure safety, protect assets and increase business efficiency. Milestone enables an open platform community that drives collaboration and innovation in the development and use of network video technology, with reliable and scalable solutions that are proven in more than 500,000 installations worldwide. Founded in 1998, Milestone is a stand-alone company in the Canon Group. For more information visit: http://www.milestonesys.com . For news and other press releases, visit our Newsroom . Click here for information on Trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005274/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom